Researchers associated with Mindbloom just published an article arguing that at-home ketamine-assisted therapy is not only safe but led to improvements (<50%) in depression and anxiety in 62% of participants. But wait, haven’t all read that maybe the services provided by Mindbloom were faced with “organizational difficulties, long wait times…

Psychedelic therapy is going mainstream — it won’t be long before these therapies are rolled out in clinics across the globe once the regulations around these substances are changed. Many believe that psychedelic therapy is the solution to the global mental health crisis. While it is hard to deny these…

Psychedelics are poised to be a solution to the global mental health crisis, and eventually, psychedelic therapy is likely to become an accessible treatment, so we should start planning now. While clinical trials are progressing with positive results, it remains unclear how or if these results will translate into the…

Up until recently, the legal issues and stigma surrounding psychedelics have deterred many traditional sources from funding such research over the past 50 years. These issues rendered funding psychedelic research a less than a favourable option for your average investor and have also stopped governments from lending a hand to…

The use of plant-derived psychedelic substances like psilocybin and ayahuasca goes back thousands of years. It wasn’t until the 1950s that psychedelics found their way into the minds and laboratories of curious researchers. During this first wave of research — and until very recently — psychedelics have remained more or…

Psychedelics as medicine are continuing to go from strength to strength. Researchers worldwide are continuing to bring drugs like MDMA and psilocybin through the clinical trial process to turn these substances into viable therapy options. With this success, you don’t have to look too far to find psychedelics in the…

Anyone following the rise of psychedelic science in recent years should be all too familiar with the efforts to patent various aspects of the psychedelic experience — from the drug themselves to methods of administering them. Many companies are scrambling to file patents for their formulations of a given psychedelic…

Psychedelic research is going from strength to strength. With roughly 50 psychedelic research papers published every month and the abundance of start-ups looking to turn psychedelics into viable therapy options — we’ve come a long from the handful of papers published each year in the early 2010s. Next to the…

Since the 1970s, psychedelic drugs have been classified as Schedule I substances — the most restrictive category. Substances in this category are believed to be devoid of any medical value, but thanks to the work of researchers around the globe, we now have the evidence that says otherwise. Despite the…